Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit
Yaron Rotman, Brent A. Neuschwander‐Tetri – 2 February 2017
Safety and efficacy of transhepatic and transsplenic access for endovascular management of portal vein complications after liver transplantation
Joon‐Young Ohm, Gi‐Young Ko, Kyu‐Bo Sung, Dong‐Il Gwon, Heung Kyu Ko – 2 February 2017 – The purpose of this article is to evaluate and compare the safety and efficacy of endovascular management of the portal vein (PV) via percutaneous transsplenic access versus percutaneous transhepatic access in liver transplantation (LT) recipients. A total of 18 patients who underwent endovascular management of PV via percutaneous transhepatic (n = 8) and transsplenic (n = 10) access were enrolled.
Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
Catarina Oliveira, Carole Fournier, Véronique Descamps, Virginie Morel, Corey A. Scipione, Rocco Romagnuolo, Marlys L. Koschinsky, Agnès Boullier, Paulo Marcelo, Jean‐Marc Domon, Etienne Brochot, Gilles Duverlie, Catherine Francois, Sandrine Castelain, Francois Helle – 2 February 2017 – The development of different cell culture models has greatly contributed to increased understanding of the hepatitis C virus (HCV) life cycle. However, it is still challenging to grow HCV clinical isolates in cell culture.
Changing pattern of biliary complications in an evolving liver transplant unit
Ashwin Rammohan, Sanjay Govil, Joy Vargese, Venugopal Kota, Mettu S. Reddy, Mohamed Rela – 2 February 2017 – Biliary complications (BCs) remain a significant cause of morbidity following liver transplantation (LT). This series of 640 LT recipients with a blend of living and deceased donor transplants was analyzed to determine the incidence, risk factors, management protocol, and outcomes in these patients. Review of a prospectively collected database of transplant recipients operated between August 2009 and June 2016 was performed.
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit
Yaron Rotman, Brent A. Neuschwander‐Tetri – 2 February 2017
The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells
Marina Vilaseca, Héctor García‐Calderó, Erica Lafoz, Oihane García‐Irigoyen, Matías A. Avila, Joan Carles Reverter, Jaume Bosch, Virginia Hernández‐Gea, Jordi Gracia‐Sancho, Joan Carles García‐Pagán – 31 January 2017 – In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary factor for portal hypertension (PH) development. Hepatic stellate cells (HSCs) play a major role increasing IHVR because, when activated, they are contractile and promote fibrogenesis.
Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind
Edoardo G. Giannini, Vincenzo Savarino – 31 January 2017
The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus
Jin Y. Choi, Jeong I. Yu, Hee C. Park, C. H. David Kwon, Jong M. Kim, Jae‐Won Joh, Gyu‐Seong Choi, Jae B. Park, Sung J. Kim, Seung H. Lee, Won‐Tae Cho, Kyo W. Lee, Byeong‐Gon Na, Dong Kyu Oh, Nuri Lee, Chan W. Cho, Sanghoon Lee, Suk‐Koo Lee – 30 January 2017
High‐dose opioid use and liver transplantation: An underestimated problem?
Shari Rogal, Mary Amanda Dew, Andrea DiMartini – 30 January 2017
Carbon monoxide ameliorates hepatic ischemia/reperfusion injury via sirtuin 1‐mediated deacetylation of high‐mobility group box 1 in rats
Jian Sun, Enshuang Guo, Jiankun Yang, Yan Yang, Shenpei Liu, Jifa Hu, Xiaojing Jiang, Olaf Dirsch, Uta Dahmen, Wei Dong, Anding Liu – 30 January 2017 – Carbon monoxide (CO) exerts protective effects on hepatic ischemia/reperfusion injury (IRI), but the underlying molecular mechanisms are not fully understood. High‐mobility group box 1 (HMGB1) is an important mediator of injury and inflammation in hepatic IRI. Here, we investigated whether CO could attenuate hepatic IRI via inhibition of HMGB1 release, particularly through sirtuin 1 (SIRT1).